Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine.

ABSTRACT:

Background

Hypomethylating agents, including azacytidine (AZA), are standard therapeutics for patients with high-risk myelodysplastic syndromes (MDS), a group of myeloid neoplasms. However, treatment schedules are not unified in real-world practice; in addition to the standard 7-day (standard-dose) schedule, shortened (reduced-dose) schedules are also used.

Aims

The aim of this study was to discover the patient group(s) which show differential efficacy between standard-and reduced-dose AZA to MDS.

Methods and results

The outcome of different AZA doses in a cohort of 151 MDS patients were retrospectively analyzed. Overall survival (OS) was not significantly different between standard- and reduced-dose AZA groups by multivariate analysis. However, an interaction was fou

SUBMITTER: Ogawa S 

PROVIDER: S-EPMC10809187 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature